Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its novel hydrophilic biomaterial platform, today announced that the Infusion Nurses Society (INS) has updated its standard of care to include innovative catheter materials, to reduce the risk of vascular access complications.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications with its advanced biomaterial platform, today announced the appointment of Dennis Byrne to the newly created role of Vice President of Sales and Marketing.

“AVI is poised to have a substantial impact on vascular access complications and their associated costs,” said James Biggin, founder and CEO of Access Vascular. “This funding, coupled with increasing demand for our ground-breaking catheters, and new data showing reduced bacterial adhesion, is yet another milestone on our path to transforming the standard of care for vascular access.”

The study, results of which were shared Oct. 14 at the annual scientific meeting of the Association for Vascular Access, compared bacterial adhesion on two polyurethane-based catheters and the HBM using in vitro blood flow and static models. The HBM demonstrated a 99.998 percent reduction in bacterial adhesion compared with the standard polyurethane catheter, and a 99.989 percent reduction compared with an augmented polyurethane material.

Access Vascular, Inc. (AVI), a medical device company addressing the most common and costly complications of intravenous therapy, today announced the publication of a peer-reviewed study of its HydroPICC® peripherally inserted central catheter (PICC) in the Journal of Materials Science: Materials in Medicine.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today shared key findings from an economic analysis published in the International Journal of Nursing and Research regarding AVI’s consistently hydrophilic PICC and midline catheters. The analysis documents millions of dollars in available cost-savings for hospitals using biomaterial-based catheters to reduce vascular access complications.

Access Vascular, Inc. (AVI), a company addressing the most common and costly vascular access complications through its advanced biomaterial platform, today announced the outcome of a peer-reviewed study published in the Journal of Infusion Nursing that demonstrated a significant reduction in complications when using AVI’s consistently hydrophilic midline catheters.

Access Vascular, Inc. (AVI) today shared initial findings from a retrospective review of patient records that demonstrates an increase in dwell times compared to other commercially-available devices and no complications when using AVI’s consistently hydrophilic materials for midline catheters.

Access Vascular, Inc. (AVI) today announced it has been named “Best New Technology Solution – Drug Delivery” in the 2022 MedTech Breakthrough Awards. AVI’s patented, groundbreaking new biomaterial-based catheters were recognized for their potential to reshape the field of vascular access and value based care at large.

Access Vascular, Inc. (AVI) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its HydroPICC® Dual-Lumen catheter. Designed and constructed using the same proprietary hydrophilic biomaterial as AVI’s single-lumen HydroPICC® and HydroMID® catheters, these devices showed significant reduction in complications such as occlusions, replacements, Deep Vein Thrombosis and phlebitis in recent studies.

Access Vascular, Inc. (AVI) today announced its biomaterial-based hydrophilic catheters received a Gold Award as the 2022 Edison Best New Product in science and medical at the 2022 Edison Awards™.

New 40,000 sqft facility offers additional advanced manufacturing capabilities as providers seek to improve medical outcomes using Access Vascular’s catheters.

Access Vascular, Inc. (AVI), today announced its partnership with Healthcare Insights (HCIS) to build a value-based care program that can more broadly support hospital customers as they deploy the company’s groundbreaking biomaterial-based catheters to improve vascular access medical and economic outcomes.

AVI’s groundbreaking new biomaterial-based cathethers were recognized for their ability to nearly eliminate the common and expensive complications that affect approximately 30% of all hospital patients with traditional polyurethane catheters inserted. This transformational technology has the potential to reshape the field of vascular access and value based care at large.